- Also known as
- Reta · LY3437943 · GGG tri-agonist
- Class
- GIP, GLP-1 and glucagon receptor agonist
- Form
- Lyophilised powder, as 10 mg, 20 mg and 30 mg vials plus a pre-filled pen
- Sizes
- 10 mg · 20 mg · 30 mg
- Storage, dry
- −20 °C, dry and dark
- Storage, mixed
- 2–8 °C, use within 28 days of mixing (as generally reported for reconstituted peptides)
- BAC water per size
- 10 mg: 2 mL · 20 mg: 3 mL · 30 mg: 3 mL
What is Retatrutide?
Classified as a GIP, GLP-1 and glucagon receptor agonist, Retatrutide takes that label as the point from which its published record begins. The work published on it is in human. Several names in the literature all point to the same material, among them Reta, LY3437943 and GGG tri-agonist. Its sequence is recorded as Single peptide chain with activity at three receptors; developed as LY3437943.. All 6 of the 6 studies set out below are controlled trials in people. Borealis Peptides provides it as lyophilised powder in 10 mg, 20 mg and 30 mg vials and a pre-filled pen for in-vitro laboratory research. It is neither a medicine nor meant for use in humans or animals.
What the research shows
| Study | Model | Dose used | Duration | Finding |
|---|---|---|---|---|
| Jastreboff AM et al.2023 · N Engl J Med · PMID 37366315 | Human, phase 2 randomised controlled trial in adults with obesity (n=338) | 1, 4, 8 or 12 mg once weekly, subcutaneous (4 and 8 mg arms started at 2 or 4 mg; 12 mg started at 2 mg), vs placebo | 48 weeks | Mean body weight change at 48 weeks was −8.7% (1 mg), −17.1% (4 mg), −22.8% (8 mg) and −24.2% (12 mg) vs −2.1% with placebo. The most common adverse events were gastrointestinal, dose-related and mostly mild to moderate. |
| Bajaj HS et al.2026 · Lancet · PMID 42250575 | Human, phase 3 randomised controlled trial in adults with type 2 diabetes (n=537) | 4, 9 or 12 mg once weekly, subcutaneous, vs placebo | 40 weeks | HbA1c fell by 1.69%, 1.86% and 1.94% with 4, 9 and 12 mg vs 0.81% with placebo, and body weight changed by −11.5%, −13.9% and −15.3% vs −2.6%. Discontinuation for adverse events was 2–5% with retatrutide and 0% with placebo. |
| Urva S et al.2022 · Lancet · PMID 36354040 | Human, phase 1b randomised multiple-ascending dose trial in type 2 diabetes (n=72) | 0.5, 1.5, 3, 3/6 or 3/6/9/12 mg once weekly, subcutaneous, vs placebo or dulaglutide 1.5 mg | 12 weeks | Treatment-emergent adverse events were reported by 63% of participants on LY3437943, 60% on dulaglutide and 54% on placebo, with gastrointestinal disorders the most frequent. The primary outcome was safety and tolerability. |
| Sanyal AJ et al.2024 · Nat Med · PMID 38858523 | Human, phase 2a randomised controlled substudy in adults with MASLD and ≥10% liver fat (n=98) | 1, 4, 8 or 12 mg once weekly, subcutaneous, vs placebo | 48 weeks (liver fat primary endpoint at 24 weeks) | Mean relative change in liver fat at 24 weeks was −42.9% (1 mg), −57.0% (4 mg), −81.4% (8 mg) and −82.4% (12 mg) vs +0.3% with placebo. Normal liver fat (<5%) was reached by 27% to 86% of the retatrutide groups and 0% on placebo. |
| Coskun T et al.2025 · Lancet Diabetes Endocrinol · PMID 40609566 | Human, phase 2 randomised controlled body-composition substudy in type 2 diabetes (n=189 enrolled; 103 with both DXA scans) | 0.5, 4, 8 or 12 mg once weekly, subcutaneous, vs placebo or dulaglutide 1.5 mg | 36 weeks | Total fat mass measured by DXA fell by 4.9% (0.5 mg), 15.2% (4 mg), 26.1% (8 mg) and 23.2% (12 mg), compared with 2.6% on dulaglutide and 4.5% on placebo. |
| Kanu C et al.2025 · Diabetes Obes Metab · PMID 40916752 | Human, exploratory analysis of a phase 2 randomised controlled trial in type 2 diabetes (n=275) | 0.5, 4, 8 or 12 mg once weekly, vs placebo or dulaglutide 1.5 mg | 24 and 36 weeks | Participants on 4 mg or more reported greater reductions in overall appetite, hunger and prospective food consumption than placebo at week 24. Lower perceived hunger and disinhibition correlated with weight reduction at week 36. |
What these studies don't show: There are trials, but they cover less ground than they might appear to. The people enrolled are a selected group, the endpoints tend to be surrogate markers in place of hard outcomes, and the follow-up is seldom long. None of that settles safety beyond the specific conditions of each trial. Confirming that the vial contains what the label states tells you nothing about whether the compound has any effect.
Every study links to its PubMed record. See all Retatrutide studies in the research library →
Retatrutide price in Canada: 10mg, 20mg and 30mg vials
Buy Retatrutide in Canada in 3 vial sizes, plus pre-filled pens and a starter kit. Prices are in Canadian dollars, you pay by Interac e-Transfer or bank transfer, and orders are shipped from Canadian stock.
| Size | Price | Per mg |
|---|---|---|
| 10 mg | $87.00 | $8.70/mg |
| 20 mg | $138.00 | $6.90/mg |
| 30 mg | $198.00 | $6.60/mg |
Pens, kits and other formats
Is Retatrutide available in Canada?
Retatrutide is not listed in the Drug Product Database as an authorized product. Its safety, efficacy and quality have not been assessed by any regulator in Canada. Borealis Peptides provides it strictly for in-vitro laboratory research, never for human or veterinary use. Read more →
Side effects reported in studies
Wherever a cited study commented on tolerability, that wording is reproduced verbatim below. Human work on this scale does not pin down a safety profile. Read more →
Retatrutide FAQ
What is Retatrutide?
In the literature Retatrutide is characterised as a GIP, GLP-1 and glucagon receptor agonist. Its published work is in human. Borealis Peptides provides it as lyophilised powder in 10 mg, 20 mg and 30 mg vials and a pre-filled pen for in-vitro laboratory research. None of this is a medicine, and it is not for human or veterinary use. The table on this page sets out each study together with its model and the result it reported.
Where can I buy Retatrutide in Canada?
We ship it inside Canada from our own stock, in 10 mg, 20 mg and 30 mg vials. Nothing goes out until that batch has been confirmed by HPLC for identity and purity. Borealis Peptides takes research orders only and delivers to research and business addresses.
Is Retatrutide legal in Canada?
Retatrutide is not listed in the Drug Product Database as an authorized product. Its safety, efficacy and quality have not been assessed by any regulator in Canada. Borealis Peptides provides it strictly for in-vitro laboratory research, never for human or veterinary use. Because Health Canada has stated that "Research Use Only" labelling does not make a product legal to use in a person, we understand it as a statement of supply, not a clearance to put it to use.
How much Retatrutide should I use?
Borealis Peptides offers no dosing, protocols or reconstitution volumes and will not supply them even when asked. In the lab the quantity is dictated by the study design, something a supplier is in no position to set. The numbers on this page are simply what particular published studies used within their own models: a record of what was done, not a recommendation.
What human evidence is there for Retatrutide?
Of the 6 studies cited, 6 are controlled trials in people, with the remainder being animal or cell work. Every row states its model, the amount used and the authors' reported finding, so each study's weight can be assessed first-hand instead of through a summary.
Does Retatrutide need refrigeration?
Keep sealed vials at −20 °C, dry and shielded from light. Once reconstituted, store at 2–8 °C. The dry powder comes to no harm in room-temperature transit and should go into the fridge on arrival. What wears down a lyophilised peptide is light and temperature swings, not the time spent in transit.
Does Retatrutide need bacteriostatic water?
The pre-filled pen arrives already in solution. Only the lyophilised vial ships dry, and that is the single format for which bacteriostatic water is relevant. It is sold separately. Each batch is run on HPLC, and the certificate you receive is for the batch that was sent to you.
How is the purity of Retatrutide confirmed?
Identity and purity are verified by HPLC for every batch rather than once per product. The certificate states which batch it covers, and that batch number is printed on the vial, so any result can be traced back to the exact material behind it. Send us your order number and we forward it.
How does Retatrutide compare with Tirzepatide and Cagrilintide?
Each carries its own published record, so a comparison means reading both. Tirzepatide and Cagrilintide have 8 cited studies and 8 cited studies on their page against 6 here. The comparison worth making is to read the two tables, together with the models each one used.
Why is Retatrutide named in a Health Canada advisory?
Because it was one of the peptides seized from sellers marketing unauthorized injectable products online. That advisory is about material sold for people to inject without authorization. Borealis Peptides provides research material for laboratory use and sells nothing for injection or for any use in a person, which is exactly where that advisory draws its line.











